Recombinant Macaca fascicularis 60S ribosomal protein L35a (RPL35A)

How does RPL35A contribute to ribosomal function in primates?

RPL35A is a component of the 60S ribosomal subunit that plays crucial roles in protein synthesis. In primates, including Macaca fascicularis, RPL35A has been shown to bind to both initiator and elongator tRNAs, positioning it at the P site, or both P and A sites of the ribosome . This strategic location enables it to participate in critical steps of translation.

Methodologically, researchers can investigate RPL35A's contribution to ribosomal function through:

• Polysome profiling after shRNA-mediated depletion of RPL35A

• Metabolic labeling of rRNA to track pre-rRNA processing

• Northern blot analysis to assess rRNA maturation

Studies have demonstrated that RPL35A is essential for the maturation of 28S and 5.8S rRNAs and 60S subunit biogenesis . When RPL35A is depleted or mutated, researchers observe defects in pre-rRNA processing, reduction in 60S subunit formation, impaired cell proliferation, and increased apoptosis .

What expression systems are available for producing recombinant Macaca fascicularis RPL35A?

Several expression systems have been successfully used for producing recombinant Macaca fascicularis RPL35A, each with distinct advantages for specific research applications:

When selecting an expression system, researchers should consider that HEK293-expressed RPL35A may better represent the native form found in primates due to appropriate post-translational modifications and protein folding environments . For studies requiring high purity, incorporating affinity tags such as His-tag followed by chromatographic techniques yields protein with ≥85% purity as determined by SDS-PAGE .

How can researchers effectively assess RPL35A's role in pre-rRNA processing?

To investigate RPL35A's role in pre-rRNA processing, researchers should employ a multi-faceted approach:

• shRNA-mediated knockdown: Design specific shRNA sequences targeting different regions of RPL35A mRNA. At least three different targeting sequences should be tested to confirm specificity and rule out off-target effects .

• Northern blot analysis: This technique allows detection of pre-rRNA processing intermediates. Collect RNA samples 6 days post-infection with lentiviral shRNA constructs to allow sufficient depletion of RPL35A .

• Metabolic labeling: Pulse-chase experiments with [³²P]orthophosphate or [³H]uridine can track the kinetics of rRNA maturation in real-time.

• Polysome profiling: This method separates and analyzes different ribosomal subpopulations to assess the impact of RPL35A depletion on ribosome assembly.

A critical methodological consideration is the use of appropriate controls. An shRNA targeting firefly luciferase serves as an ideal negative control since it has no mammalian target . Flow cytometry sorting of GFP-positive cells ensures analysis of only successfully transduced cells.

Research has shown that RPL35A depletion specifically affects maturation of 28S and 5.8S rRNAs without significantly impacting 18S rRNA processing, confirming its role in large ribosomal subunit biogenesis .

What is the relationship between RPL35A mutations and Diamond-Blackfan anemia pathophysiology?

Diamond-Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by anemia, congenital abnormalities, and cancer predisposition. At least 14 RPL35A gene mutations have been identified in individuals with DBA .

Methodologically, researchers investigating this relationship should:

• Sequence analysis: Screen patient cohorts for mutations in the coding exons, intron/exon boundaries, and promoter regions of RPL35A . Compare findings with control populations to distinguish pathogenic mutations from polymorphisms.

• Functional validation: Test identified mutations through:

  • Pre-rRNA processing analysis in patient-derived cells

  • Complementation assays to determine if wild-type RPL35A rescues cellular defects

  • Creation of isogenic cell lines with CRISPR/Cas9 to study mutation effects in controlled genetic backgrounds

• Animal models: Develop zebrafish or mouse models with RPL35A mutations to study developmental and hematopoietic effects.

Research indicates that RPL35A mutations likely cause ribosomal dysfunction, leading to increased apoptosis of blood-forming cells in the bone marrow and resulting in anemia . Abnormal regulation of cell division or inappropriate triggering of apoptosis may contribute to the other health problems and unusual physical features observed in DBA patients .

What techniques are most effective for studying RPL35A's interaction with other ribosomal components?

Understanding RPL35A's interactions within the ribosome requires specialized techniques:

• Cryo-electron microscopy (cryo-EM): Provides high-resolution structural data of RPL35A within intact ribosomes or ribosomal subunits.

• Cross-linking and mass spectrometry (CXMS): Identifies direct interaction partners by chemically cross-linking proteins in proximity before mass spectrometric analysis.

• Co-immunoprecipitation (Co-IP): Using antibodies against tagged recombinant RPL35A to pull down interaction partners.

• Proximity labeling methods: BioID or APEX2 fused to RPL35A can biotinylate nearby proteins, which are then identified by mass spectrometry.

• Ribosome profiling: Provides insight into the positioning of RPL35A during active translation.

When implementing these techniques, researchers should consider that RPL35A has been shown to bind to both initiator and elongator tRNAs, placing it at a critical position in the ribosome (P site or P and A sites) . This strategic location makes it an important player in translation initiation and elongation, suggesting it may interact with factors beyond the core ribosomal components.

What are the optimal storage and handling conditions for maintaining recombinant RPL35A stability?

Maintaining the stability and activity of recombinant RPL35A requires careful consideration of storage and handling conditions:

Critical methodological considerations include:

• Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and aggregation .

• For proteins stored in urea-containing buffers, gradual dialysis is recommended before using in functional assays to prevent interference with biological activity.

• Verify protein integrity after long-term storage using SDS-PAGE or activity assays before proceeding with critical experiments.

• For studies requiring preserved enzymatic or binding activity, stability should be confirmed using functional assays rather than relying solely on physical appearance or SDS-PAGE results.

How can researchers effectively validate RPL35A antibody specificity for immunological studies?

Ensuring antibody specificity is crucial for reliable immunological studies of RPL35A. A comprehensive validation approach includes:

• Western blot analysis:

  • Test antibody against recombinant RPL35A with and without tags

  • Compare with lysates from cells with normal, overexpressed, and knocked-down RPL35A levels

  • Include closely related proteins (other ribosomal proteins) to check for cross-reactivity

• Immunoprecipitation validation:

  • Perform IP followed by mass spectrometry to confirm target identity

  • Conduct reverse IP with anti-tag antibodies when using tagged recombinant proteins

• Peptide competition assays:

  • Pre-incubate antibody with purified RPL35A or specific peptides

  • Should eliminate specific signal in subsequent applications

• Knockout/knockdown controls:

  • Use CRISPR/Cas9 knockout or shRNA knockdown cells as negative controls

  • Particularly important for distinguishing specific signal from background

• Cross-species reactivity testing:

  • If antibody is claimed to work across species, test with recombinant RPL35A from multiple species

  • Important when studying conserved proteins like RPL35A in different model organisms

When selecting antibodies, researchers should note that RPL35A has high sequence homology across species, which can be advantageous for cross-species studies but requires careful validation of specificity .

What purification strategies yield the highest purity and biological activity for recombinant RPL35A?

Optimal purification of recombinant RPL35A involves multiple chromatography steps, with strategy selection depending on the expression system and tags used:

• For His-tagged RPL35A:

  • Initial capture: Immobilized metal affinity chromatography (IMAC) using Ni-NTA or Co²⁺ resins

  • Secondary purification: Size exclusion chromatography to remove aggregates and impurities

  • Achievable purity: ≥85-90% by SDS-PAGE

• For Fc-Avi-tagged RPL35A:

  • Initial capture: Protein A/G affinity chromatography for Fc tag binding

  • Secondary purification: Monomeric avidin column for Avi tag

  • Final polishing: Ion exchange chromatography

  • Achievable purity: ≥85% by SDS-PAGE

• Tag removal considerations:

  • If tag removal is required, incorporate TEV or PreScission protease cleavage sites

  • Perform reverse IMAC to remove cleaved tags and uncut protein

  • Conduct final polishing with ion exchange chromatography

Critical quality control measures include:

• Endotoxin testing (should be <1.0 EU per μg)

• Circular dichroism to confirm proper folding

• Activity assays to verify functionality (RNA binding assays for RPL35A)

• Mass spectrometry to confirm protein identity and detect modifications

For applications requiring highly pure protein, researchers should aim for preparations with ≥90% purity as determined by SDS-PAGE and analytical size exclusion chromatography .

What emerging technologies might advance our understanding of RPL35A function in comparative primate studies?

Several cutting-edge technologies show promise for deepening our understanding of RPL35A function across primate species:

• Single-molecule imaging techniques:

  • Allows visualization of individual RPL35A molecules during ribosome assembly and translation

  • Can reveal species-specific differences in binding kinetics and localization

• AlphaFold and structural biology integration:

  • Computational structure prediction combined with cryo-EM data

  • Enables comparative analysis of subtle structural differences in RPL35A across primate species

• Ribosome profiling with long-read sequencing:

  • Provides insight into RPL35A's role in translation of specific mRNA subsets

  • Can identify species-specific translational regulation patterns

• CRISPR-based screens in primate cell lines:

  • Systematic analysis of genetic interactions with RPL35A

  • Identification of species-specific regulatory networks

• Spatially-resolved transcriptomics and proteomics:

  • Maps RPL35A distribution and function across different cell types and tissues

  • Could reveal tissue-specific roles in different primate species

These technologies could help address unresolved questions about why mutations in RPL35A and other ribosomal proteins lead to tissue-specific diseases despite their ubiquitous expression . Comparative studies across primate species might reveal evolutionary adaptations in ribosomal function and regulation that contribute to species-specific traits.